
## Francesca Morgante

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7101557/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurology, 2018, 75, 1132.	9.0	455
2	Abnormal associative plasticity of the human motor cortex in writer's cramp. Brain, 2003, 126, 2586-2596.	7.6	353
3	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain, 2006, 129, 1059-1069.	7.6	286
4	Levodopaâ€induced dyskinesia in Parkinson disease: Current and evolving concepts. Annals of Neurology, 2018, 84, 797-811.	5.3	225
5	Cortical and spinal abnormalities in psychogenic dystonia. Annals of Neurology, 2006, 59, 825-834.	5.3	195
6	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.1	194
7	Homeostatic-like plasticity of the primary motor hand area is impaired in focal hand dystonia. Brain, 2005, 128, 1943-1950.	7.6	193
8	Abnormal plasticity of sensorimotor circuits extends beyond the affected body part in focal dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 985-990.	1.9	177
9	Abnormal sensorimotor plasticity in organic but not in psychogenic dystonia. Brain, 2009, 132, 2871-2877.	7.6	173
10	Distinct changes in cortical and spinal excitability following high-frequency repetitive TMS to the human motor cortex. Experimental Brain Research, 2005, 161, 114-124.	1.5	140
11	Validation of the Italian version of the Movement Disorder Society—Unified Parkinson's Disease Rating Scale. Neurological Sciences, 2013, 34, 683-687.	1.9	123
12	Paired Associative Stimulation of Left and Right Human Motor Cortex Shapes Interhemispheric Motor Inhibition based on a Hebbian Mechanism. Cerebral Cortex, 2009, 19, 907-915.	2.9	117
13	Rapid-rate paired associative stimulation of the median nerve and motor cortex can produce long-lasting changes in motor cortical excitability in humans. Journal of Physiology, 2006, 575, 657-670.	2.9	115
14	Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation on Interhemispheric Inhibition. Journal of Neurophysiology, 2005, 94, 1668-1675.	1.8	111
15	Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. Movement Disorders, 2009, 24, 1001-1008.	3.9	104
16	Disease modification and biomarker development in Parkinson disease. Neurology, 2020, 94, 481-494.	1.1	103
17	Enhanced Long-Term Potentiation-Like Plasticity of the Trigeminal Blink Reflex Circuit in Blepharospasm. Journal of Neuroscience, 2006, 26, 716-721.	3.6	94
18	Psychogenic facial movement disorders: Clinical features and associated conditions. Movement Disorders, 2012, 27, 1544-1551.	3.9	93

#	Article	IF	CITATIONS
19	Long-term assessment of the risk of spread in primary late-onset focal dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 392-396.	1.9	83
20	<scp><i>GBA</i>â€Related</scp> Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	3.9	83
21	Facial Emotion Recognition and Expression in Parkinson's Disease: An Emotional Mirror Mechanism?. PLoS ONE, 2017, 12, e0169110.	2.5	83
22	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 76-82.	1.9	82
23	Treatable inherited rare movement disorders. Movement Disorders, 2018, 33, 21-35.	3.9	79
24	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism and Related Disorders, 2007, 13, 528-531.	2.2	77
25	Outcome measurement in functional neurological disorder: a systematic review and recommendations. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 638-649.	1.9	77
26	Functional neurological disorders in Parkinson disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 566-571.	1.9	76
27	Pisa syndrome in Parkinson disease. Neurology, 2015, 85, 1769-1779.	1.1	72
28	Tremor in primary adult-onset dystonia: prevalence and associated clinical features. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 404-408.	1.9	71
29	Long lasting effects of transcranial direct current stimulation on motor imagery. NeuroReport, 2004, 15, 1287-1291.	1.2	69
30	Interactions between long latency afferent inhibition and interhemispheric inhibitions in the human motor cortex. Journal of Physiology, 2005, 563, 915-924.	2.9	67
31	Clinical features of dystonia: a pathophysiological revisitation. Current Opinion in Neurology, 2008, 24, 484-490.	3.6	66
32	Abnormal tactile temporal discrimination in psychogenic dystonia. Neurology, 2011, 77, 1191-1197.	1.1	66
33	Is central fatigue in multiple sclerosis a disorder of movement preparation?. Journal of Neurology, 2011, 258, 263-272.	3.6	65
34	Obsessive-compulsive disorder: A "sensory-motor―problem?. International Journal of Psychophysiology, 2014, 92, 74-78.	1.0	65
35	Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. Movement Disorders, 2017, 32, 1557-1565.	3.9	65
36	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 33-42.	1.8	65

#	Article	IF	CITATIONS
37	Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management. Movement Disorders, 2016, 31, 1785-1795.	3.9	62
38	Impulsive-compulsive behaviors in <i>parkin</i> -associated Parkinson disease. Neurology, 2016, 87, 1436-1441.	1.1	61
39	Diagnostic agreement in patients with psychogenic movement disorders. Movement Disorders, 2012, 27, 548-552.	3.9	60
40	Reduced facial expressiveness in Parkinson's disease: A pure motor disorder?. Journal of the Neurological Sciences, 2015, 358, 125-130.	0.6	52
41	Treatment Recommendations for Tardive Dyskinesia. Canadian Journal of Psychiatry, 2019, 64, 388-399.	1.9	52
42	Corticospinal excitability during motor imagery of a simple tonic finger movement in patients with writer's cramp. Movement Disorders, 2005, 20, 1488-1495.	3.9	49
43	The Assessment and Treatment of Antipsychotic-Induced Akathisia. Canadian Journal of Psychiatry, 2018, 63, 719-729.	1.9	48
44	Dopamine agonists restore cortical plasticity in patients with idiopathic restless legs syndrome. Movement Disorders, 2009, 24, 710-715.	3.9	46
45	Age at onset and symptom spread in primary adultâ€onset blepharospasm and cervical dystonia. Movement Disorders, 2012, 27, 1447-1450.	3.9	46
46	Impairment of sensory-motor integration in patients affected by RLS. Journal of Neurology, 2010, 257, 1979-1985.	3.6	45
47	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. Movement Disorders Clinical Practice, 2020, 7, 920-929.	1.5	45
48	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic―neurology. European Journal of Neurology, 2021, 28, 1752-1758.	3.3	45
49	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
50	Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. Neurological Sciences, 2019, 40, 89-95.	1.9	44
51	Impairment of sensory-motor plasticity in mild Alzheimer's disease. Brain Stimulation, 2013, 6, 62-66.	1.6	43
52	Environmental risk factors and clinical phenotype in familial and sporadic primary blepharospasm. Neurology, 2011, 77, 631-637.	1.1	42
53	Psychogenic Movement Disorders. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1383-1396.	0.8	41
54	Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. European Journal of Neurology, 2020, 27, 975-984.	3.3	41

#	Article	IF	CITATIONS
55	Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. Schizophrenia Research, 2014, 152, 344-349.	2.0	38
56	The Italian Dystonia Registry: rationale, design and preliminary findings. Neurological Sciences, 2017, 38, 819-825.	1.9	35
57	Long-duration Parkinson's disease: Role of lateralization of motor features. Parkinsonism and Related Disorders, 2013, 19, 77-80.	2.2	34
58	Hypomimia in Parkinson's disease: an axial sign responsive to levodopa. European Journal of Neurology, 2020, 27, 2422-2429.	3.3	34
59	Prediction of the Levodopa Challenge Test in Parkinson's Disease Using Data from a Wrist-Worn Sensor. Sensors, 2019, 19, 5153.	3.8	33
60	[1231]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophrenia Research, 2012, 139, 40-45.	2.0	32
61	Lower limb involvement in adultâ€onset primary dystonia: frequency and clinical features. European Journal of Neurology, 2010, 17, 242-246.	3.3	31
62	Levetiracetam in Tardive Dyskinesia. Clinical Neuropharmacology, 2006, 29, 265-268.	0.7	29
63	The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®). Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988860.	3.5	29
64	Maladaptive Plasticity in Levodopa-Induced Dyskinesias and Tardive Dyskinesias: Old and New Insights on the Effects of Dopamine Receptor Pharmacology. Frontiers in Neurology, 2014, 5, 49.	2.4	28
65	Know thyself: Exploring interoceptive sensitivity in Parkinson's disease. Journal of the Neurological Sciences, 2016, 364, 110-115.	0.6	28
66	Speech and gait in Parkinson's disease: When rhythm matters. Parkinsonism and Related Disorders, 2016, 32, 42-47.	2.2	27
67	Subthalamic deep brain stimulation induces finely-tuned gamma oscillations in the absence of levodopa. Neurobiology of Disease, 2021, 152, 105287.	4.4	27
68	Associative cortico-cortical plasticity may affect ipsilateral finger opposition movements. Behavioural Brain Research, 2011, 216, 433-439.	2.2	26
69	Eye symptoms in relatives of patients with primary adultâ€onset dystonia. Movement Disorders, 2012, 27, 305-307.	3.9	26
70	Non-invasive brain stimulation for dystonia: therapeutic implications. European Journal of Neurology, 2017, 24, 1228-e64.	3.3	26
71	Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD. Journal of Clinical Medicine, 2020, 9, 3931.	2.4	26
72	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. Journal of Neurology, 2020, 267, 2949-2960.	3.6	26

#	Article	IF	CITATIONS
73	A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease. Sensors, 2021, 21, 5437.	3.8	26
74	Motor cortex abnormalities in amyotrophic lateral sclerosis with transcranial direct-current stimulation. Muscle and Nerve, 2007, 35, 620-624.	2.2	25
75	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Expert Opinion on Pharmacotherapy, 2012, 13, 2269-2280.	1.8	25
76	Normal sensorimotor plasticity in complex regional pain syndrome with fixed posture of the hand. Movement Disorders, 2017, 32, 149-157.	3.9	25
77	Abnormal nociceptive processing occurs centrally and not peripherally in pain-free Parkinson disease patients: A study with laser-evoked potentials. Parkinsonism and Related Disorders, 2017, 34, 43-48.	2.2	25
78	Parkinson's Disease Symptoms Have a Distinct Impact on Caregivers' and Patients' Stress: A Study Assessing the Consequences of the COVIDâ€19 Lockdown. Movement Disorders Clinical Practice, 2020, 7, 865-867.	1.5	25
79	Functional motor phenotypes: to lump or to split?. Journal of Neurology, 2021, 268, 4737-4743.	3.6	25
80	Soft signs in movement disorders: friends or foes?. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 961-962.	1.9	24
81	Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19. Journal of Neurology, 2021, 268, 3995-3997.	3.6	23
82	Successful treatment of Holmes tremor by levetiracetam. Movement Disorders, 2008, 23, 2101-2103.	3.9	22
83	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. Journal of Neural Transmission, 2020, 127, 1435-1439.	2.8	22
84	DyNeuMo Mk-1: Design and pilot validation of an investigational motion-adaptive neurostimulator with integrated chronotherapy. Experimental Neurology, 2022, 351, 113977.	4.1	22
85	Finely-tuned gamma oscillations: Spectral characteristics and links to dyskinesia. Experimental Neurology, 2022, 351, 113999.	4.1	22
86	Brain dysfunction in uremia: a question of cortical hyperexcitability?. Clinical Neurophysiology, 2005, 116, 1507-1514.	1.5	21
87	Mirror movements in Parkinson's disease: effect of dopaminergic drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1194-1195.	1.9	21
88	Consensus paper: Use of transcranial magnetic stimulation to probe motor cortex plasticity in dystonia and levodopa-induced dyskinesia. Brain Stimulation, 2009, 2, 108-117.	1.6	21
89	Nigro-striatal involvement in primary progressive freezing gait: Insights into a heterogeneous pathogenesis. Parkinsonism and Related Disorders, 2012, 18, 578-584.	2.2	21
90	Acting without being in control: Exploring volition in Parkinson's disease with impulsive compulsive behaviours. Parkinsonism and Related Disorders, 2017, 40, 51-57.	2.2	21

#	Article	IF	CITATIONS
91	Biased Visuospatial Attention in Cervical Dystonia. Journal of the International Neuropsychological Society, 2018, 24, 22-32.	1.8	21
92	Pain processing in functional and idiopathic dystonia: An exploratory study. Movement Disorders, 2018, 33, 1340-1348.	3.9	21
93	Worldwide barriers to genetic testing for movement disorders. European Journal of Neurology, 2021, 28, 1901-1909.	3.3	21
94	Pain in Parkinson's disease and the role of the subthalamic nucleus. Brain, 2021, 144, 1342-1350.	7.6	21
95	Dystonia as complication of thalamic neurosurgery. Parkinsonism and Related Disorders, 2019, 66, 232-236.	2.2	19
96	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurological Sciences, 2012, 33, 585-593.	1.9	18
97	Can we predict development of impulsive–compulsive behaviours in Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 476-481.	1.9	18
98	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. Parkinsonism and Related Disorders, 2020, 71, 40-43.	2.2	18
99	Efficacy of pregabalin in a case of stiff-person syndrome: Clinical and neurophysiological evidence. Journal of the Neurological Sciences, 2012, 314, 166-168.	0.6	17
100	Improvement with Duloxetine in Primary Progressive Freezing Gait. Neurology, 2010, 75, 2130-2132.	1.1	15
101	Spatial and Temporal High Processing of Visual and Auditory Stimuli in Cervical Dystonia. Frontiers in Neurology, 2017, 8, 66.	2.4	15
102	Impaired Temporal Processing of Tactile and Proprioceptive Stimuli in Cerebellar Degeneration. PLoS ONE, 2013, 8, e78628.	2.5	15
103	DYT2 screening in early-onset isolated dystonia. European Journal of Paediatric Neurology, 2017, 21, 269-271.	1.6	13
104	Dyskinesiaâ€Hyperpyrexia Syndrome in Parkinson's Disease: A Heat Shock–Related Emergency?. Movement Disorders Clinical Practice, 2018, 5, 534-537.	1.5	13
105	Hiding in Plain Sight: Functional Neurological Disorders in the News. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 361-367.	1.8	13
106	Fatigue in hypokinetic, hyperkinetic, and functional movement disorders. Parkinsonism and Related Disorders, 2021, 86, 114-123.	2.2	13
107	Computer-vision based method for quantifying rising from chair in Parkinson's disease patients. Intelligence-based Medicine, 2022, 6, 100046.	2.4	13
108	Symptom severity in patients with functional motor symptoms: Patient's perception and doctor's clinical assessment. Parkinsonism and Related Disorders, 2015, 21, 529-532.	2.2	12

#	Article	IF	CITATIONS
109	The Italian tremor Network (TITAN): rationale, design and preliminary findings. Neurological Sciences, 2022, 43, 5369-5376.	1.9	12
110	Dystonia. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1225-1241.	0.8	11
111	Stimulation of the subthalamic area modulating movement and behavior. Parkinsonism and Related Disorders, 2014, 20, 1298-1300.	2.2	11
112	Emotional facedness in Parkinson's disease. Journal of Neural Transmission, 2018, 125, 1819-1827.	2.8	11
113	Spread of dystonia in patients with idiopathic adultâ€onset laryngeal dystonia. European Journal of Neurology, 2018, 25, 1341-1344.	3.3	11
114	Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease. Movement Disorders, 2021, 36, 2126-2135.	3.9	10
115	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. Frontiers in Neurology, 2021, 12, 646841.	2.4	10
116	Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports. Frontiers in Pharmacology, 2020, 11, 315.	3.5	9
117	Impact of Cognitive Reserve and Premorbid IQ on Cognitive and Functional Status in Older Outpatients. Brain Sciences, 2021, 11, 824.	2.3	9
118	Levodopa–carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age. Journal of Neurology, 2021, 268, 1728-1737.	3.6	9
119	Acute parkinsonism as first manifestation of systemic lupus erythematosus unmasked by CMV infection. Neurological Sciences, 2014, 35, 2019-2021.	1.9	8
120	Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. Frontiers in Pharmacology, 2018, 9, 608.	3.5	8
121	Exploring three levels of interoception in people with functional motor disorders. Parkinsonism and Related Disorders, 2021, 86, 15-18.	2.2	8
122	Movement disorders phenomenology in focal motor seizures. Parkinsonism and Related Disorders, 2019, 61, 161-165.	2.2	7
123	Upper camptocormia in Parkinson's disease: Neurophysiological and imaging findings of both central and peripheral pathophysiological mechanisms. Parkinsonism and Related Disorders, 2020, 71, 28-34.	2.2	6
124	Head drop in Huntington disease: Insights into the pathophysiology. Neurology, 2013, 81, 769-770.	1.1	5
125	Movement disorders and chronic psychosis. Neurology: Clinical Practice, 2017, 7, 163-169.	1.6	5
126	Role of pedunculopontine nucleus in sleep-wake cycle and cognition in humans: A systematic review of DBS studies. Neurobiology of Disease, 2019, 128, 53-58.	4.4	5

8

#	Article	IF	CITATIONS
127	Future Scenarios for Levodopa-Induced Dyskinesias in Parkinsonââ,¬â"¢s Disease. Frontiers in Neurology, 2015, 6, 76.	2.4	4
128	Parkinsonian axial signs in schizophrenia. Parkinsonism and Related Disorders, 2017, 36, 89-92.	2.2	4
129	Sleep disturbances are mainly improved by deep brain stimulation of the subthalamic nucleus. Movement Disorders, 2019, 34, 154-155.	3.9	4
130	Analyses of peripheral blood dendritic cells and magnetic resonance spectroscopy support dysfunctional neuroâ€immune crosstalk in Tourette syndrome. European Journal of Neurology, 2021, 28, 1910-1921.	3.3	4
131	Changes in Corticospinal Circuits During Premovement Facilitation in Physiological Conditions. Frontiers in Human Neuroscience, 2021, 15, 684013.	2.0	4
132	Andersonâ€Fabry Disease: A Rare Cause of Levodopaâ€Responsive Earlyâ€Onset Parkinsonism. Movement Disorders Clinical Practice, 2021, 8, S32-S34.	1.5	4
133	Functional gait disorders: Demographic and clinical correlations. Parkinsonism and Related Disorders, 2021, 91, 32-36.	2.2	4
134	Deep brain stimulation of the ventralis oralis anterior thalamic nucleus is effective for dystonic tremor. Parkinsonism and Related Disorders, 2020, 81, 8-11.	2.2	4
135	Ethnic Differences in Dystonia Prevalence and Phenotype. Movement Disorders, 2022, 37, 1323-1325.	3.9	4
136	Transcranial magnetic stimulation as trigger of dystonic attacks in a patient affected by paroxysmal kinesigenic dyskinesia. Neurological Sciences, 2005, 26, 362-366.	1.9	3
137	The six gaps in the search of neuroprotection for Parkinson's disease. Expert Review of Neurotherapeutics, 2012, 12, 111-113.	2.8	3
138	Treating Congenital Mirror Movements with Botulinum Toxin. Movement Disorders Clinical Practice, 2017, 4, 895-897.	1.5	3
139	<i>LRP10</i> : A novel disease gene bridging Parkinson's disease and dementia with Lewy body. Movement Disorders, 2019, 34, 47-47.	3.9	3
140	Spatial Integration of Somatosensory Inputs during Sensory-Motor Plasticity Phenomena Is Normal in Focal Hand Dystonia. Neural Plasticity, 2018, 2018, 1-7.	2.2	2
141	Predictive modeling of spread in adultâ€onset isolated dystonia: Key properties and effect of tremor inclusion. European Journal of Neurology, 2021, 28, 3999-4009.	3.3	2
142	Repetitive transcranial magnetic stimulation in the treatment of dystonia. , 2012, , 501-511.		2
143	Cortical excitability in patients with resistance to thyroid hormone compared to patients: with hypothyroidism and euthyroid controls: a transcranial magnetic stimulation study. Archives Italiennes De Biologie, 2016, 154, 68-77.	0.4	2
144	Lower Prevalence of Chronic Pain in Manifest Huntington's Disease: A Pilot Observational Study. Brain Sciences, 2022, 12, 676.	2.3	2

#	Article	IF	CITATIONS
145	FACIAL EMOTION EXPRESSIVENESS AND FACIAL EMOTION RECOGNITION IN PARKINSON'S DISEASE: HOW MUCH DOES ALEXITHYMIA COUNT?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e3-e3.	1.9	1
146	Rhythmical Involuntary Movements (Tremor and Tremor-Like Conditions). , 2016, , 207-263.		1
147	Heat, Hormones, and Functional Movement Disorders: Further Sources of Symptom Variability. Movement Disorders, 2021, 36, 2213-2214.	3.9	1
148	No Adverse Effects following Off-Label Magnetic Resonance Imaging in a Patient with Two Deep Brain Stimulation Systems: A Case Report. Stereotactic and Functional Neurosurgery, 2022, 100, 253-258.	1.5	1
149	Cognitive and mood disorders in elderly patients with Parkinson's disease. Archives of Gerontology and Geriatrics, 2001, 33, 33-36.	3.0	0
150	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism and Related Disorders, 2008, 14, 266-267.	2.2	0
151	Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing. Parkinsonism and Related Disorders, 2016, 22, e97-e98.	2.2	0
152	Axial Disorders of Movement. , 2016, , 361-435.		0
153	Lack of Organization or Coordination of Voluntary Muscle Activity. , 2016, , 155-205.		0
154	Commentary: <scp>Andersonâ€Fabry</scp> Disease: A Rare Cause of Levodopaâ€Responsive Early Onset Parkinsonism. Movement Disorders Clinical Practice, 2021, 8, S35-S36.	1.5	0
155	Poverty and Slowness of Voluntary Movement. , 2016, , 1-47.		0
156	Patterned or Repetitive Movements and/or Abnormal Posturing. , 2016, , 265-303.		0